Clive Meanwell's new obesity biotech, Metsera, unveils early GLP-1 data with an eye on Phase 3 next year

Kyle LaHucik

Senior Reporter

Metsera, the well-funded obesity biotech from Population Health Partners and ARCH Venture Partners, has unveiled its first clinical data just a few months after emerging …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Clive Meanwell's new obesity biotech, Metsera, unveils early GLP-1 data with an eye on Phase 3 next year

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

Biogen, UCB declare Phase 3 lupus win and prep a second trial, but details are scant

Gene therapy maker bluebird bio cuts costs again, lays off staff

Flagship’s AI biotech Generate lands $65M upfront in Novartis deal, as first clinical readouts near

Exclusive: Constructive Bio raises $58M for synbio work, and Nobel laureate joins board

House passes reauthorization of rare pediatric voucher program

PDCs vs. ADCs: A New Frontier in Targeted Cancer Therapies and the Potential for Development Partnerships

Clive Mean­well's new obe­si­ty biotech, Met­sera, un­veils ear­ly GLP-1 da­ta with an eye on Phase 3 next year

Senior Reporter

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

Clive Meanwell's new obesity biotech, Metsera, unveils early GLP-1 data with an eye on Phase 3 next year